Skip to main content
. 2019 May 16;10(4):1297–1317. doi: 10.1007/s13300-019-0630-6

Fig. 5.

Fig. 5

Cost-effectiveness acceptability curve for the primary analysis versus dulaglutide, based on SUSTAIN 7. DKK 2017 Danish kroner, QALY quality-adjusted life year